Kymera in the News

Cells have intricate mechanisms to remove damaged or mis-expressed proteins that could be deleterious to cellular function. This process is mediated by a process called ubiquitination, mediated by a special class of proteins called E3 ligases. Ubiquitin is the tag that’s added that signals that a protein should be moved to the biochemical garbage can. Dr. Juliet WIlliams of Kymera describes how their company has used modeling and A.I. to design molecular linkers that connect a protein that needs to be degraded with the machinery to tag it for destruction.

The company has a program called Kymera Cares, an effort that allows employees to give back, volunteer, and fundraise for organizations helping local communities throughout the greater Boston area as well as patients and their support systems.

The FDA has granted fast track designation to KT-333 for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) and relapsed/refractory peripheral T-cell lymphoma (PTCL).

Kymera Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for KT-333 to treat Relapsed/Refractory (R/R) Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL).

A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research.

Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement

With more attention being paid to work-life balance and employee burnout, a slower summer may not be a bad thing. The biopharma industry in particular is often go-go-go, but industry leaders still look for ways to stop and smell the roses while keeping innovation on track.

Sanofi will advance an experimental inflammatory disease drug into Phase 2 clinical testing after its biotechnology company partner Kymera Therapeutics reported Wednesday what it described as encouraging results from a small study.

Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa (HS) and atopic dermatitis (AD), breaking ground to take protein degradation outside the field of oncology and into inflammatory disease indications.

Kymera and Sanofi plan to move ahead with the skin drug that the French drugmaker paid $150 million in cash in 2020 to partner on, after positive Phase I results on the IRAK4 degrader they’ve been working on for a pair of skin conditions.